Ray Dalio
ADMA icon

Ray Dalio’s ADMA Biologics ADMA Stock Holding History

Ray Dalio’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.25M Buy
472,108
+285,637
+153% +$4.51M 0.02% 458
2025
Q4 		$3.4M Buy
186,471
+126,189
+209% +$2.13M 0.01% 636
2025
Q3 		$884K Buy
+60,282
New +$1.03M ﹤0.01% 863

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ray Dalio's ADMA Position: Q1 2026 in Review

Ray Dalio increased its ADMA Biologics (ADMA) stake by 153% in Q1 2026, buying an estimated $4.51M and bringing the position to 472,108 shares worth $4.25M. The position accounts for 0.02% of the portfolio, ranked #458.

Ray Dalio first reported a position in ADMA in Q3 2025 and has held it in 3 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Ray Dalio held 472,108 shares of ADMA Biologics worth $4.25M as of Q1 2026.
  • Ray Dalio bought 285,637 ADMA Biologics shares in Q1 2026, an estimated $4.51M.
  • ADMA Biologics made up 0.02% of Ray Dalio's portfolio in Q1 2026, its #458 holding.
  • Ray Dalio first reported a position in ADMA Biologics in Q3 2025 and has held it in 3 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.